Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corporation Common Stock
(NY:
CVM
)
0.4310
+0.0161 (+3.88%)
Official Closing Price
Updated: 8:00 PM EST, Jan 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,798,538
Open
0.4141
Bid (Size)
0.4252 (1)
Ask (Size)
0.4337 (3)
Prev. Close
0.4149
Today's Range
0.4100 - 0.4399
52wk Range
0.3701 - 3.080
Shares Outstanding
61,493,229
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CEL-SCI Announces Closing of $5 Million Offering
December 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 30, 2024
Via
Benzinga
Performance
YTD
+3.88%
+3.88%
1 Month
-24.39%
-24.39%
3 Month
-60.09%
-60.09%
6 Month
-64.38%
-64.38%
1 Year
-82.12%
-82.12%
More News
Read More
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
December 30, 2024
Via
Benzinga
Crude Oil Gains 1%; Chicago PMI Falls In December
December 30, 2024
Via
Benzinga
Exposures
Fossil Fuels
CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024
August 16, 2024
Via
InvestorPlace
US Stocks Open Lower; Dow Tumbles 600 Points
December 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Cel-Sci Shares Premarket On Monday?
December 30, 2024
Via
Benzinga
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
December 30, 2024
Via
Benzinga
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
December 30, 2024
Via
Benzinga
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
December 30, 2024
Via
Benzinga
CEL-SCI Announces Pricing of $5 Million Public Offering
December 29, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering of Common Stock
December 27, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
December 12, 2024
From
CEL-SCI Corporation
Via
Business Wire
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
November 07, 2024
From
CEL-SCI Corporation
Via
Business Wire
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
October 22, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
October 01, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
September 16, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
September 10, 2024
From
CEL-SCI Corporation
Via
Business Wire
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
September 04, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
August 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
August 02, 2024
Via
Investor Brand Network
Exposures
Product Safety
CEL-SCI Announces Closing of $10.8 Million Offering
July 29, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $10.8 Million Offering
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.